EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
64actual
Sites
26
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-01 | actual | When the study began enrolling |
| Primary completion | 2026-05-13 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-01-05 | estimated | The whole study's end, after follow-up |
| First posted | 2024-01-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Transthyretin Amyloid Cardiomyopathy
Interventions
- Drug: Eplontersen
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercent change of serum TTR concentration from baseline
measured up to 24 weeks
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed